Wait, What? “Exosome” Is Often Used More Confidently Than the Evidence Allows
Many papers and products call small extracellular particles “exosomes”.
But proving endosomal origin is difficult.
Modern field guidelines therefore encourage the broader term:
extracellular vesicle, or EV,
unless biogenesis has been demonstrated.
The first professional lesson is nomenclature discipline.
The One-Sentence Answer
Learn extracellular vesicles by separating what was measured—a membrane-bound extracellular particle—from what is inferred about its origin, cargo, target cell and biological function.
Stage 1: EVs Are Membrane-Enclosed Particles
They are released by cells and cannot replicate independently.
They can contain:
- proteins;
- lipids;
- RNA;
- metabolites.
Stage 2: EVs Come From Several Biogenesis Routes
Common routes include:
- endosomal multivesicular-body release;
- direct budding from the plasma membrane;
- membrane fragmentation during cell death.
The resulting particle populations overlap in size.
Size alone does not prove origin.
Stage 3: Exosomes Are an Endosomal Biogenesis Concept
In the classic model, inward budding inside endosomes creates intraluminal vesicles.
Multivesicular bodies later fuse with the plasma membrane and release those vesicles extracellularly.
That released population is often called exosomal.
Stage 4: Microvesicle-Like EVs Bud Outward
Some EVs form directly from the plasma membrane.
Again, real populations overlap.
Stage 5: Cargo Sorting Is Selective but Imperfect
Proteins, lipids and RNAs are not packaged randomly.
ESCRT-related machinery, tetraspanins, lipids and RNA-binding proteins can bias cargo selection.
But every EV does not contain the same cargo.
Stage 6: One Cell Releases Many EV Types
A single cell can release heterogeneous vesicles with different:
- size;
- density;
- proteins;
- cargo;
- destinations.
“Cell-derived EV” is not one uniform product.
Stage 7: EVs Can Bind, Fuse or Be Endocytosed
Target cells may interact with EVs through:
- surface receptors;
- endocytosis;
- membrane fusion;
- phagocytic uptake.
Uptake does not automatically prove functional cargo delivery to the cytoplasm.
Stage 8: Functional Delivery Is Harder to Prove Than Uptake
Fluorescent signal inside a cell may represent:
- membrane-bound EVs;
- endosomal trapping;
- dye aggregates.
To prove biological transfer, experiments need stronger controls.
Stage 9: EVs Can Carry RNA
miRNAs and other RNAs can be detected in EV preparations.
But low copy number matters.
A biologically meaningful signalling claim requires enough molecules to alter the receiver.
Stage 10: EVs Can Carry Proteins and Lipids
Surface proteins may affect targeting.
Enzymes or ligands can alter recipient-cell signalling.
Lipids can also act as bioactive cargo.
Stage 11: EVs Participate in Immune Communication
Immune-cell-derived EVs can carry:
- antigens;
- cytokine-related signals;
- receptors.
They can stimulate or suppress responses depending on context.
Stage 12: Tumours Release EVs Too
Cancer-associated EVs can alter:
- immune responses;
- stromal cells;
- vascular behaviour.
They may also enter circulation and become biomarker candidates.
Stage 13: Blood Is a Difficult Measurement Environment
Plasma contains:
- lipoproteins;
- protein aggregates;
- platelets;
- many EV populations.
Separating EVs from look-alike particles is difficult.
Stage 14: Ultracentrifugation Does Not Produce Pure “Exosomes”
High-speed centrifugation enriches particles by sedimentation behaviour.
It can co-isolate:
- protein aggregates;
- lipoproteins;
- other vesicles.
Method name is not proof of biological purity.
Stage 15: Size-Exclusion Chromatography Uses Another Property
SEC separates particles by hydrodynamic behaviour.
It can reduce some soluble-protein contamination.
It still does not uniquely classify biogenesis.
Stage 16: Nanoparticle Tracking Analysis Measures Motion
NTA estimates particle size and concentration from Brownian motion.
It detects particles.
It does not automatically prove those particles are EVs.
Stage 17: Electron Microscopy Adds Structure
EM can show membrane-bound particles and morphology.
Preparation can distort shape.
A beautiful vesicle image does not establish cargo function.
Stage 18: Flow Cytometry Has Size Limits
Conventional flow cytometers can struggle with very small EVs.
Modern high-sensitivity instruments improve detection, but calibration is essential.
Stage 19: Tetraspanins Are Useful but Not Universal
CD9, CD63 and CD81 are commonly used EV-associated markers.
Not every EV expresses them equally.
Not every tetraspanin-positive particle proves a specific biogenesis route.
Stage 20: MISEV Guidelines Emphasise Operational Reporting
The field increasingly asks researchers to report:
- source;
- isolation method;
- characterization;
- positive/negative markers;
- functional controls.
This improves reproducibility.
Stage 21: EV Biomarkers Need Receiver-Specific Validation
A circulating EV signature may correlate with disease.
To become a useful biomarker, it must survive tests of:
- specificity;
- sensitivity;
- reproducibility;
- pre-analytical variation.
Stage 22: Pre-Analytical Handling Matters
Delay before processing, platelet activation, freeze–thaw cycles and anticoagulant choice can change measured EV populations.
The sample pipeline becomes part of the biology.
Stage 23: Single-EV Analysis Is a Major Frontier
Rather than averaging millions of particles, new technologies measure individual EVs.
This reveals heterogeneity hidden in bulk assays.
Stage 24: EV Therapeutics Are an Engineering Challenge
Researchers are exploring EVs as delivery vehicles.
Key constraints include:
- cargo loading;
- targeting;
- stability;
- dose;
- manufacturing;
- purity.
Natural origin does not make delivery automatically safe or effective.
Stage 25: Professional EV Science Is a Provenance Problem
The key question becomes:
What particle was isolated, how was its cellular origin established, what cargo reached which recipient compartment, and what functional effect was demonstrated with appropriate controls?
Misconceptions Worth Hunting
- Every small EV is an exosome.
- Ultracentrifugation purifies exosomes.
- NTA particle count equals EV count.
- Uptake proves functional cargo delivery.
- CD63 proves endosomal origin.
- EV RNA is always abundant enough to signal.
- Natural vesicles are automatically safe therapies.
- One EV preparation is homogeneous.
Transfer Check
Isolate 100-nm particles from plasma.
Can you call them exosomes from size alone?
No.
Detect fluorescent signal in recipient cells.
Does that prove cytosolic RNA transfer?
No.
Find a disease-correlated EV marker.
Does that prove clinical utility?
No.
Model Limits
Isolation methods enrich rather than perfectly purify. Fluorescent dyes can create artifacts. EV nomenclature depends on evidence of origin. Bulk assays hide particle heterogeneity.
Professional EV science keeps:
particle identity + biogenesis evidence + cargo amount + recipient route + functional control
visible together.
The Quiet Ending
The beginner asks, “What is inside an exosome?”
The developing scientist asks, “How do we know it was an exosome?”
And the professional asks:
Which particle provenance, cargo-delivery evidence and recipient-cell mechanism justify the communication claim we are making?
eduKate Sengkang 